Neoantigen Peptide Service

Advantages of GenScript Neoantigen Peptide Service

Enhanced Success in Peptide Synthesis with NeoPre 2.0

Dedicated GMP Production Line

• Accelerated Delivery Time: Research-grade peptides can be delivered in 5 days, and other peptides within one week, ensuring timely project progress.
• High Predictability and Success Rates: 86% accurate predictability rate for synthesis difficulty leads to a 98% success rate for difficult neoantigen peptide synthesis.
• Sequence Modification Feature: The tool can pre-screen and suggest modifications to sequences, helping customers ensure successful synthesis and improve overall outcomes.
• Improved Product Quality: The system recommends the best synthesis method for each peptide, ensuring consistently high-quality synthesis results.
• Higher Customer Satisfaction: Faster and more reliable delivery improves client satisfaction and trust in our services.
• NeoPre; GenScript’s Proprietary Bioinformatics Tool for Difficult Neoantigen Peptide Synthesis
• GenScript's Technical Advances for Difficult Neoantigen Peptide Synthesis | GenScript

• Our facility includes a Grade A isolator dedicated to achieve sterile filtration and aseptic filling assisting human injection purposes.
• Highly customized services, such as different vial sizes and customized single batch filling volumes.
• Comprehensive sterility assurance system:
  • Contamination Control Strategy (CCS)
  • Aseptic Process Simulation (APS)
  • Vaporized Hydrogen Peroxide (VHP)
  • Sanitize in Place (SIP)
• Highly customized aseptic processing service
  • Different vials size
  • Different filling volume
  • One batch of up to 3000 vials

FAQs

• What are neoantigen?

  Neoantigens are new cancer antigens expressed in tumor tissue but not in healthy tissue. They are unique to individual tumors and make ideal targets for personalized immunotherapies. Neoantigens are generated through mutations and are highly specific. They are not recognized as self-antigens, leading to a strong immune response.

• How are they related to personalized vaccines?

  Neoantigens, unlike common tumor-associated antigens, are not recognized as self-antigens and therefore elicit a strong immune response. Directly targeting neoantigens can enhance their immunogenicity and stimulate a potent anti-tumor immune response. Once a neoantigen forms, it is unlikely to mutate again and escape therapeutic targeting. Personalized cancer vaccines that target multiple neoantigens simultaneously can prevent immune escape if one neoantigen mutates. Each neoantigen can be matched to specific T cell receptors, allowing for in vitro analysis of their immune response before potential therapeutic use.

• What are the advantages of GenScript’s Neoantigen peptide?

  Neoantigen peptides usually vary in length, charge and hydrophobicity leading to difficulties in synthesis and purification. So, GenScript has developed the NeoPre algorithm, which is able to determine the peptide synthesis difficulty based on sequence alone. With the NeoPre algorithm, we are able to synthesize neoantigen peptides with over 98% success rate. We also have a great turnaround time of overall about 10 days. Once your peptides have been generated, GenScript offers library design tools such as alanine scanning, overlapping, T-cell truncation to assist you optimize any neoantigen sequence. So, these are the advantages of using our Neoantigen peptide as we promise to provide a one stop solution for all our peptide users.

• What is the capacity of GenScript’s neoantigen peptide production?

  GenScript is able to provide neoantigen peptides with length up to 35 AA with purity> 95% and compliance GMP requirement to succeed your clinical trials.

• What makes neoantigen peptides so difficult to produce?

  Neoantigen peptides are difficult to be produced due to several factors. Firstly, their length can vary, with some being 9-11 amino acids long and others exceeding 25 amino acids. Peptides with over 20 amino acids are particularly challenging to synthesize. Secondly, neoantigens may contain charge-modifying amino acids that are not commonly found in natural tumor-associated antigens. This can make synthesis more difficult as specific isoelectric points are required for certain synthetic steps. Thirdly, the random amino acid insertions or deletions that generate neoantigens often introduce hydrophobic side chains, leading to increased aggregation and limited solubility in water. Purification becomes challenging as a result. Additionally, different applications within therapeutic development require varying yields, mass, purity, and percentage of target peptide, making it cumbersome to find a reliable provider that can accommodate these diverse requirements. GenScript has tailored its neoantigen peptide service to address these challenges and provide high-quality hydrophobic peptides as needed.

• Is there a waitlist to start production?

  GenScript has the capacity to begin your Neoantigen peptide synthesis project without any waiting time. Contact our commercial team to ensure your project stays on schedule.

• What method did you use to synthesize neoantigen peptides?

  Based on difficulty and project details we help you pick the applicable synthesis platform to maximize success. It can be microwave technology, liquid-phase technology or solid-phase technology.

• What type of QC is needed for Neoantigen peptides?

  All GenScript peptides undergo Total Quality Management testing through AccuPep™ quality control services. We provide more than 14 types of QC.

• Is your neoantigen peptide sterile or non-sterile?

  We can produce non-sterile neoantigen peptide in the RUO line and GMP facility. In case the sterile neoantigen peptide is requested, our GMP facility with Sterility Assurance (sterilizing filtration and fill/finish in Class A isolator) could reach.

• What is the sequence length available for Neoantigen peptide?

  GenScript is able to provide up to 35 AA.

• What is the maximum quantity per batch in your GMP facility for neoantigen peptide?

  Each batch of Neoantigen peptide is up to 150mg.

• Is there any way to predict the success rate of Neoantigen peptides?

  Yes, GenScript has developed a predictive algorithm, NeoPre , which is able to determine peptide synthesis difficulty based on sequence alone. NeoPre can then recommend the most efficient approach to synthesizing peptides using one of GenScript’s many synthesis platforms.